Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436312 | 0.85 | SIRT1 (0.40) | HDAC1SIRT1SIRT2TLR9TLR8 | |
| SCHEMBL3434229 | 0.81 | SIRT2 (0.44) | SIRT1SIRT2 | |
| SCHEMBL4506882 | 0.78 | HDAC1 (0.51) | HDAC1SIRT1 | |
| SCHEMBL3435656 | 0.76 | SLC6A9 (0.53) | SIRT1SIRT2TLR8TLR7DRD2 | |
| SCHEMBL3434276 | 0.76 | SLC6A9 (0.53) | SIRT1SIRT2TLR8TLR7DRD2 | |
| SCHEMBL4186458 | 0.74 | DRD2 (0.55) | HDAC1TLR9TLR8TLR7DRD2 | |
| SCHEMBL31008735 | 0.70 | HSD11B1 (0.33) | TLR9TLR8TLR7RAB9A | |
| SCHEMBL30226481 | 0.70 | HSD11B1 (0.33) | TLR9TLR8TLR7RAB9A | |
| SCHEMBL31009117 | 0.70 | HSD11B1 (0.33) | TLR9TLR8TLR7RAB9A | |
| SCHEMBL3435649 | 0.67 | MEN1 (0.45) | SIRT1SIRT2CYP2C19DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | HDAC1 372/4885SIRT1 225/4885SIRT2 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.